Main > > >LUNG CANCER. *

ChemoTherapy (CT)-Induced Neutropenia>
Decrease>
>Prior to Pt/Etoposide or Topotecan
Contg.-Regimen
>Trilaciclib Inj.
[Extensive Stage Small Cell Lung Cancer
(ES SCLC)]
USA Approval Date: 2021. 02.12.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2021. 02.16.




COMPANION DIAG.:
"Biopsy>Liquid Biopsy CTCs+ctDNA"
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2018. 06.12.




DIAG.: AI Tomography+Fused Imaging+ Cloud-based Machine Learning+Multi-Moda- lity Image Registration Platform.
USA FDA Clearance Date: 2019. 05.
(*) Company : Body Vision Medical.
TradeMark: LungVision™ 2.0
Web-Site :
www.bodyvisionmedical.com/
UpDate: 2020. 02.20.




DIAG.: Blood Test.
EU Approval Date: 2017. 05.31.
IL Approval Date: 2019. 05.15.
(*) Company (IL): Best Med Opinion
www.best-med-
opinion.com/english/
Company (UK): OncImmune Ltd.
TradeMark : EarlyCDT-Lung
Web-Site :
oncimmune.com/lung-cancer-blood-
test/
UpDate: 2020. 01.05.




DIAG.: Blood Test.
CN & USA Availability: Yes.
(*) Company (USA); Patents; TradeMark
& Web-Site Available on Request.
UpDate: 2020. 01.19.




DIAG.: Computed Tomography (CT). Compu-
ter Aided Detection (CAD).
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.28.




DIAG.: Computed Tomography (CT). Compu-
ter Aided Detection (CAD)
Version 3.0 With SmartFlow Feature and Other Upgrades.
Release Date: 2017. 11.21.
(*) Company : Eon Health.
Web-Site: eonhealth.com
UpDate: 2018. 10.28.




DIAG.: Computed Tomography (CT). Compu-
ter Assisted Diagnostic (CADx) Software.
CA Approval Date: ?
EU Approval Date: 2019. 07.12.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.02.




DIAG.: Computed Tomography (CT). Nodu-
le Detection Based on Deep Learning.
USA Approval Date: 2020. 07.09.
(*) Company; TradeMark; USA Patent
APP. & Web-Site Available on Re
quest.
UpDate: 2020. 09.27.




DIAG.: Computed Tomography (CT). Pulmo-
nary Nodule Detecting Artificial Inte-
lligence (AI) Solution.
JP Approval Date: 2019. 12.
KR Approval Date: 2020. 04.29.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 04.30.




DIAG.: Computed Tomography (CT). Repor-
ting & Tracking SoftWare.
(*) Company : MRS Systems Inc.
TradeMark: Aspen Lung
Web-Site :
mrsys.com/products/aspen-lung
UpDate: 2018. 10.28.




DIAG.: EB19-J10U Ultrasound Video Bron- choscope.
USA Launch Date: 2019. 12.17.
(*) Company : Hoya Corp.>BUS.>Medical>
Pentax Medical
Web-Site :
www.pentaxmedical.com/pentax
UpDate: 2019. 12.27.




DIAG.: Genomic Sequencing Classifier (GSC).
Built on Company s RNA Whole-Transcrip tome Sequencing and Machine-Learning platform. The test uses novel “Field of Injury” science to identify genomic changes associated with lung cancer in current or former smokers by using a simple brushing of the person s airway,
which is collected during a bronchoscopy
USA Launch Date: 2019. 06.26.
(*) Company; Patent; TradeMark & Web-
Sites Available on Request.
UpDate: 2020. 01.13.




DIAG.: Liquid Biopsy Test.
EU CE-IVD Mark Date: 2017.12.19.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.28.




DIAG.: Peripheral Lung Biopsy.
Robotic-Assisted Endoluminal Platform.
USA Approval Date: 2019. 02.19.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.28.




Onco.>RadioTherapy>BrachyTherapy>Low Ra-
te Dose (LRD) BrachyTherapy.
>Indications Potential>
>atypical meningioma
>non-small-cell lung cancer
>ocular melanoma
>Indications Used>
>colorectal cancer
>gynecological cancer
>head and neck cancer
>pancreatic cancer
>soft tissue sarcomas
USA Approval Date: 2014. 08.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 11.25.




TREAT.: Alectinib Capsules.
(NSCLC>METASTATIC>ALK+)
CN Approval Date : 2018. 08.20.
EU Approval Date : 2017. 02.21.
JP Approval Date : 2014. 07.
TW Approval Date : 2017. 02.27.
USA Approval Date: 2015. 12.11.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.29.




TREAT.: Afatinib Tablets.
(NSCLC>EGFR+>METASTATIC).
Companion Diagnostics>Liquid Biopsy>
>USA Launch Date: 2015. 03.10.
>Company : BioCept Inc.
EU Approval Date : 2013. 09.25.
USA Approval Date: 2018. 01.16.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.28.




TREAT.: Afatinib Tablets.
(NSCLC>Squamous>METASTATIC>Previously
Treated with Pt CT)
EU Approval Date : 2013. 09.25.
USA Approval Date: 2016. 04.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.28.




TREAT.: Almonertinib Tablets>
(NSCLC>EGFR T790M+>METASTATIC)
>Progressed>EGFR TKI Therapy.
CN Approval Date: 2020. 03.19.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 03.20.




TREAT.: AtezolizuMAb Inj. for IV Use.
(NSCLC>METATASTIC>Non-Squamous>EGFR- or ALK-)
+Abraxane ® + CarboPlatin (2)
+BevacizuMAb+Paclitaxel+Carboplatin (1)
USA Approval Date: 2018. 12.05. (1)
USA Approval Date: 2019. 12.03. (2)
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.27.




TREAT.: AtezolizuMAb Inj. for IV Use.
(NSCLC>METASTATIC>PD-L1+).
>Not Has Abnormal “EGFR”/“ALK" Gene
>Tried Pt-CT & Not Works & Tumor>
Has Abnormal “EGFR” /“ALK” Gene
Received “EGFR” /“ALK” Inhibitor
Medicine that did Not Work or ..
USA Approval Date: 2016. 10.18.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.29.




TREAT.: AterolizuMAb Inj. for IV Use.
(NSCLC>METASTATIC>PD-L1>High+)
USA Approval Date: 2020. 05.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.24.




TREAT.: AtezolizuMAb Inj. for IV Use.
(SCLC>METASTATIC)
+CT>Carboplatin+Etoposide
1st Line Treat.
USA Approval Date: 2019. 03.18.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.20.




TREAT.: BevacizuMAb+Erlotinib. BioSimi-
lar.
(NSCLC>Non-Squamous>METASTATIC or Recu-
rrent).
>with EGFR-Activating Mutations
USA Approval Date: 2017. 09.14.
USA Launch Date: 2019. 07.18.
(*) Company : Amgen
TradeMark: MVASI
UpDate: 2019. 11.12.




TREAT.: BevacizuMAb+Erlotinib. BioSimi-
lar.
(NSCLC>Non-Squamous>METASTATIC or Recu-
rrent).
>with EGFR-Activating Mutations
EU Approval Date : 2019. 02.19.
USA Approval Date: 2019. 06.28.
(*) Company : Pfizer.
TradeMark: ZIRABEV
UpDate: 2020. 01.08.




TREAT.: BevacizuMAb+Erlotinib. Brand.
(NSCLC>Non-Squamous>METASTATIC or Recu-
rrent).
>with EGFR-Activating Mutations.
EU>Approval>Date: 2016. 06.08.
(*) Company : Roche.
TradeMark: Avastin (BevacizuMAb)
TradeMark: Tarceva (Erlotinib)
UpDate: 2018. 11.03.




TREAT.: Brigatinib Tablets.
(NSCLC>METASTATIC>ALK+).
Companion Diagnostics>
>cfRNA Liquid Biopsy (Blood Test)
>Company: Circulogene Theranostics.
>Launch Date: 2017. 05.23.
EU Approval Date: 2018. 11.27.
USA Approval Date: 2017. 04.29. (2)
USA Approval Date: 2020. 05.22. (1)
(1): 1st Line Treat.
(2): 2nd Line Treat.>Crizotinib
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.28.




TREAT.: Capmatinib Tablets.
(NSCLC>METASTATIC>METex14+)
JP Approval Date : 2020. 06.29.
USA Approval Date: 2020. 05.06.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.27.




TREAT.: CemipliMAb-rwlc.
(NSCLC>METASTATIC>PD-1+>50%>1st Line)
USA Approval Date: 2021. 02.22.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2021. 02.23.




TREAT.: Ceritinib Capsules.
(NSCLC>METASTATIC>ALK+).
Companion Diagnostics>
>Liquid Biopsy>Blood Test.
>USA Launch Date: 2014. 11.12.
>Company: BioCept Inc.
EU>First Line Treat. OK : 2017. 06.29.
USA>First Line Treat. OK: 2017. 05.26.
USA>Progressed on Crizotinib: 2014.04.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.29.




TREAT.: Crizotinib Capsules.
(NSCLC>METASTATIC>ALK+ or ROS1+).
ALK: Anaplastic Lymphoma Kinase.
Companion Diagnostics ALK(+)>
>Company: BioCept Inc.
Blood Test (Liquid Biopsy)
USA Launch: 2014. 11.12.
Company: Circulogene Theranostics.
Blood Test (Liquid Biopsy)
USA Launch: 2017. 05.23.
Companion Diagnostics ROS1(+)>
>ROS1 Fusion Kit>
CN Approval Year: 2014.
EU Approval Year: 2013.
JP Approval Date: 2017. 02.03.
Company: Amoy Diagnostics
>DNA LIquid Biopsy>Blood Test.
USA Launch Date: 2015. 01.20.
Company : BioCept Inc.
>cfRNA LIquid Biopsy>(Blood Drop Test)
USA Launch Date: 2017. 05.23.
Company: Circulogene Theranostics
>Oncomine Dx Target
USA Approval Date: 2017. 06.22.
Company: Thermo Fisher Scientific
EU ROS1(+) Approval Date : 2016. 08.31.
USA ALK(+) Approval Date : 2011. 08.26.
USA ROS1(+) Approval Date: 2016. 03.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.29.




TREAT.: Dabrafenib Capsules+Trametinib
Tablets.
(NSCLC>METASTATIC>With BRAF V600E Muta-
tion).
EU Approval Date : 2017. 04.
USA Approval Date: 2017. 06.23.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.02.




TREAT.: Dacomitinib Tablets.
(NSCLC>EGFR+>METASTATIC).
>EGFR exon 19 deletion or exon 21
L858R substitution mutations as
detected by an FDA-approved test.
EU Approval Date: 2019. 04.03.
USA Approval Date: 2018. 09.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.04.




TREAT.: DoceTaxel Inj. Alcohol-Free.
(NSCLC>METASTATIC)
+Cisplatin for Unresectable UnTreated ..
Single Agent after Pt CT Failure
USA Approval Date: 2015. 12.28.
USA Launch Date: 2016. 02.02.
(*) Company; Patents; TradeMark & PR
Web-Site Available on Request.
UpDate: 2018. 10.29.




TREAT.: DoceTaxel Inj. Concentrate, In-
traVenous Infusion (IV)
(NSCLC>METASTATIC)
+Cisplatin for Unresectable UnTreated ..
Single Agent after Pt CT Failure
USA Initial Approval: 1996
(*) Company : sanofi-aventis U.S. LLC
Patent : Expired
TradeMark: Taxotere
UpDate: 2018. 10.29.




TREAT.: DurvaluMAb Inj. For IV Use.
(NSCLC>METASTATIC>PD-L1+).
EU Approval Date: 2021. 01.15>
>dosing option, a 1,500mg fixed dose
every four weeks
USA Approval Date: 2018. 02.19.
USA Approval Date: 2020. 11.20>
>dosing option, a 1,500mg fixed dose
every four weeks
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.10.




TREAT.: Entrectinib Capsules.
(NSCLC>METASTATIC>ROS1+)
Kinase Inhibition.
USA Approval Date: 2019. 08.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 12.06.




TREAT.: Erlotinib.HCl Tablets. Brand
(NSCLC>EGFR+>METASTATIC).
>EGFR exon 19 deletion or exon 21
L858R substitution mutations as
detected by an FDA-approved test.
Companion Diagnostics>
>USA Launch Date: 2015. 03.10.
>Liquid Biopsy
>Company: BioCept Inc.
EU Approval Date: 2005. 09.
USA Approval Date: 2004. 11.
(*) Companies; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.29.




TREAT.: Erlotinib.HCl Tablets. Generic.
(NSCLC>EGFR+>METASTATIC).
>EGFR exon 19 deletion or exon 21
L858R substitution mutations as
detected by an FDA-approved test.
Companion Diagnostics>
>USA Launch Date: 2015. 03.10.
>Liquid Biopsy
>Company: BioCept Inc.
USA Launch Date: 2019. 11.13.
(*) Company : Armas Pharmaceuticals.
UpDate: 2019. 11.14.




TREAT.: Erlotinib.HCl Tablets. Generic.
(NSCLC>EGFR+>METASTATIC).
>EGFR exon 19 deletion or exon 21
L858R substitution mutations as
detected by an FDA-approved test.
Companion Diagnostics>
>USA Launch Date: 2015. 03.10.
>Liquid Biopsy
>Company: BioCept Inc.
USA Final Approval Date: 2019. 11.12.
(*) Company: Breckenridge Pharma. Inc.
UpDate: 2019. 11.18.




TREAT.: Erlotinib.HCl Tablets. Generic.
(NSCLC>EGFR+>METASTATIC).
>EGFR exon 19 deletion or exon 21
L858R substitution mutations as
detected by an FDA-approved test.
Companion Diagnostics>
>USA Launch Date: 2015. 03.10.
>Liquid Biopsy
>Company: BioCept Inc.
(*) Company : Cipla.
TradeMark: ERLOCIP
Web-Site :
ciplamed.com/content/erlocip-tablets
UpDate: 2018. 10.29.




TREAT.: Erlotinib.HCl Tablets. Generic.
(NSCLC>EGFR+>METASTATIC).
>EGFR exon 19 deletion or exon 21
L858R substitution mutations as
detected by an FDA-approved test.
Companion Diagnostics>
>USA Launch Date: 2015. 03.10.
>Liquid Biopsy
>Company: BioCept Inc.
USA Launch Date: 2019. 05.10.
(*) Company: Mylan.
UpDate: 2020. 01.02.




TREAT.: Gefitinib.HCl Tablets.
(NSCLC>EGFR+>METASTATIC).
Companion Diagnostics Test>
>USA Approval: 2017. 06.22.
>Company : Thermo Fisher Scientific
>TradeMark : Oncomine Dx Target Test.
Approved in AU; CA; JP & USA.
(*) Company : AstraZeneca.
Patent : Expired.
TradeMark: Iressa.
Web-Site : www.iressa-usa.com
UpDate: 2018. 10.28.




TREAT.: Gemcitabine.HCl Inj.+CisPlatin.
(NSCLC).
USA Initial Approval Year: 1996.
(*) Company : Eli Lilly.
Patent : Expired.
TradeMark: Gemzar.
Web-Site :
pi.lilly.com/us/gemzar.pdf
UpDate: 2018. 10.28.




TREAT.: Lorlatinib Tablets.
(NSCLC>METASTATIC>ALK+)
whose disease has progressed on>
>crizotinib and at least one other ALK
inhibitor for metastatic disease or
>alectinib as the first ALK inhibitor
therapy for metastatic disease or
>ceritinib as the first ALK inhibitor
therapy for metastatic disease
EU Approval Date: 2019. 05.07.
USA Approval Date: 2018. 11.02.
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2019. 05.08.




TREAT.: Lurbinectedin for Inj.
(SCLC>METASTATIC)
USA Approval Date: 2020. 06.15.
(*) Companies; Patent; TradeMark &
Web-Site Available on Request.
UpDate: 2020. 09.28.




TREAT.: NivoluMAb Inj. for IV Use.
(NSCLC>METASTATIC>PD-L1+)
>Not Has Abnormal “EGFR”/“ALK" Gene.
>Tried Pt-CT & Not Works & Tumor>
Has Abnormal “EGFR” /“ALK” Gene>
Received “EGFR” /“ALK” Inhibitor>
Medicine that did Not Work or ..
Mechanism: PD-1 Inhibitor.
CA; USA; Approved.
CN Approval Date: 2018. 06.15.
EU Approval Date: 2015. 07.20.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.17.




TREAT.: NivoluMAb+IpilimuMAb Inj. for
IV Use.
(NSCLC>METASTATIC>PD-L1>1 %)
USA Approval Date: 2020. 05.15.
(*) Company; Patents; & TradeMark Avai-
lable on Request.
UpDate: 2020. 09.21.




TREAT.: NivoluMAb+IpilimuMAb+Pt CT Inj.
for IV Use.
(NSCLC>METASTATIC or RECURRENT).
CA Approval Date : 2020. 08.11.
EU Approval Date: 2020. 11.06.
USA Approval Date: 2020. 05.26.
(*) Company; Patents & TradeMark Avai-
lable on Request.
UpDate: 2021. 02.14.




TREAT.: NivoluMAb Inj. for IV Use.
(SCLC>METASTATIC>Pt CT & one other line of therapy).
USA Approval Date: 2018. 08.17.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.17.




TREAT.: Osimertinib.
(NSCLC>EGFR+>METASTATIC).
2nd Line>after EGFR tyrosine kinase inhibitor (TKI) therapy.
Companion Diagnostics Test>Roche
EGFR mutations>exon 19 deletions or exon 21 L858R mutations
BR 1st Line Approval : 2018. 04.16.
CA 2nd Line Approval : 2016. 07.11.
CN 2nd Line Approval : 2017. 03.27.
USA 1st Line Approval: 2018. 04.18.
USA 2nd Line Approval: 2017. 03.30.
USA Adjuvant Treat. : 2020. 12.21.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2021. 02.10.




TREAT.: PacliTaxel Albumin-Bound Parti-
cles for Injectable Suspension.
(NSCLC>METASTATIC).
+CarboPlatin.
>Cannot be Treated with Surgery/RT.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.29.




TREAT.: PembrolizuMAb Inj.
(NSCLC>METASTATIC>PD-L1+).
>Not Has Abnormal “EGFR”/“ALK" Gene
>Tried Pt-CT & Not Works & Tumor>
Has Abnormal “EGFR” /“ALK” Gene
Received “EGFR” /“ALK” Inhibitor
Medicine that did Not Work or ..
EU Approval Date : 2017. 01.31.
JP Approval Date : 2016. 12.19.
USA Approval Date: 2016. 10.24.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.29.




TREAT.: PembrolizuMAb Inj.>
(NSCLC>Stage III>METASTATIC>PD-L1+)
>MonoTherapy
>Not Abnormal “EGFR” or “ALK" Gene
>Not Candidates for Surgical Resection
or ChemoRadiation.
USA Approval Date: 2019. 04.11.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 04.13.




TREAT.: PembrolizuMAb Inj.+Carboplatin+
(Nab)Paclitaxel.
(NSCLC>Squamous>METASTATIC).
CN Approval Date: 2019. 11.26.
EU Approval Date: 2019. 03.14.
JP Approval Date: 2019. 01.03.
USA Approval Date: 2018. 10.30.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 01.01.




TREAT.: PembrolizuMAb Inj.+Pemetrexed+Pt CT.
(NSCLC>Non-Squamous>METASTATIC>EGFR- or
ALK-).
EU Approval Date : 2018. 09.10.
JP Approval Date : 2019. 01.03.
USA Approval Date: 2018. 08.20.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 01.04.




TREAT.: Pemetrexed for Inj. (U>Ea)
(NSCLC>Non-Squamous>METASTATIC or Recu-
rrent).
USA Final Approval: 2020. 02.10.
(*) Company; Patent; PR Web-Site &
TradeMark Available on Request.
UpDate: 2020. 02.11.




TREAT.: Pemetrexed for Inj. (U>El)
(NSCL>Non-Squamous>METASTATIC or Recu-
rrent).
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 11.03.




TREAT.: Pemetrexed for Inj.+Pembrolizu MAb+Pt CT
(NSCLC>Non-Squamous>METASTATIC>EGFR- or
ALK-).
USA Approval Date: 2019. 01.31.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 02.01.




TREAT.: Porfimer Na. PhotoDynamic Thera- py. (NSCLC>EndoBronchial Cancer)
USA Initial Approval: 1995.
(*) Company : Pinnacle Biologics.
Patent : Expired
TradeMark: Photofrin
UpDate: 2018. 10.29.




TREAT.: Pralsetinib Capsules.
(NSCLC>Metastatic>RET Fusion+).
Companion Diagnostics>
>USA Approval Date: 2020. 09.08.
USA Approval Date: 2020. 09.04.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2020. 09.20.




TREAT.: RadioTherapy (RT). Stereotactic Body RadioTherapy (SBRT). Transponder.
(NSCLC).
USA FDA 510k Clearance: 2018. 04.20.
(*) Company; Description; Patents;
TradeMark & Web-Site Available on
Request.
UpDate: 2018. 10.28.




TREAT.: Selpercatinib Capsules.
(NSCLC>METASTATIC>RET Fusion+)
USA Approval Date: 2020. 05.08.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2020. 09.22.




TREAT.: SintiliMAb Inj.+Pemetrexed+Pt
ChemoTherapy (CT).
(NSCLC>Non-Squamous>1st Line)
CN Approval Date: 2021. 02.03.
(*) Company; Patents; PR Web-Site &
TradeMark Available on Request.
UpDate: 2021. 02.16.




TREAT.: Tepotinib Tablets.
(NSCLC>METASTATIC>METex14+)
JP Approval Date : 2020. 03.
USA Approval Date: 2021. 02.03.
(*) Company & TradeMark Available on
Request.
UpDate: 2021. 02.19.




TREAT.: TislelizuMAb+Carboplatin+(Nab)-Paclitaxel.
(NSCLC Squamous MET.)
CN Approval Date: 2021. 01.13.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2021. 02.13.




TREAT.: Vinorelbine Tartrate Inj.
(NSCLC>METASTATIC)
(*) Company : GlaxoSmithKLine
Patent : Expired
TradeMark: Navelbine
UpDate: 2018. 10.29.


>LUNG CANCER. *'s products
This section has no products